State investments and regulatory framework
Uzbekistan’s pharmaceutical market is among the fastest-growing in the Eurasian region, with an average annual growth rate of 16% in US dollar terms over the past three years.
For comparison, Kazakhstan’s market grew by 14%, Kyrgyzstan’s by 13%, Russia’s by 12%, and Belarus’s by 10%, according to IQVIA’s market analysis.
A market for major players
IQVIA’s latest research, published in July 2023, reveals that the leading players in Uzbekistan’s pharmaceutical market over the past year were World Medicine (4.01%), KRKA (3.6%), and Sanofi (2.81%).
Top pharmaceutical brands in monetary terms include EVRYSDI, Natrium Chloridum, Ceftriaxone, Qupen, and Rinoxil, according to IQVIA.
At the International Pharmaceutical Forum, Anastasia Kruglova, IQVIA’s Eurasian Cluster General Manager, noted that Uzbekistan’s pharmaceutical market depends on state investment and a supportive legislative framework for further growth.
In IQVIA’s view, meeting these conditions could attract significant interest from international pharmaceutical companies.
The company also expects these positive trends to drive further localisation of production in Uzbekistan, expand clinical trials, and increase the output of local medicines.
Data-driven health solutions
IQVIA is a global leader in applying data, technology, advanced analytics, and expertise to improve healthcare and enhance quality of life. The company provides pharmaceutical market players with analytical, technological, and informational solutions, including data processing methodologies, product directories, and classification sets. IQVIA’s mission is to build an innovative global healthcare system.
In Uzbekistan, IQVIA operates within the Commonwealth of Independent States (CIS) region, which includes nine countries: Uzbekistan, Russia, Kazakhstan, Belarus, Azerbaijan, Georgia, Moldova, Kyrgyzstan, and Armenia.
IQVIA’s regional services include retail and state market audits for pharmaceuticals and medical equipment, consulting, primary market research, and technological solutions.
IQVIA also maintains OneKey, a healthcare professional and pharmacy database, which includes 31,360 medical professionals, 2,700 organisations, and over 9,800 pharmacies.
In addition, IQVIA supports drug market entry by optimising clinical trial processes. Since 1997, the company has completed more than 500 trials, with results validated by the FDA (U.S. Food and Drug Administration), EMA (European Medicines Agency), and Russia’s Ministry of Health.
The company’s consulting services span R&D, portfolio development, market launch, commercialisation, and market expansion.
IQVIA further assists clients with recruitment and team-building for specific projects, develops adaptive field force models, and supports marketing efforts and retail partnerships.
